Review article: Helicobacter pylori and gastro-oesophageal reflux disease - Clinical implications and management

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 2, 1999, Pages 117-127

  O'Connor, H J ^a,b  

^a Tullamore Co   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ARTICLE; ATROPHIC GASTRITIS; DISEASE COURSE; DRUG EFFICACY; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOPATHOLOGY; HUMAN; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL;

BARRETT ESOPHAGUS; GASTRITIS, ATROPHIC; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; OMEPRAZOLE;

EID: 0033052538     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00460.x     Document Type: Article

References (108)

1. McDougall NI, Johnston BT, Kee F, Collins IS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
2. Locke GR, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
3. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gastroenterol 1997; 112(Suppl.): A113(Abstract).
4. Baldi F. Prevalence of reflux esophagitis (RE) in Italy. Gastroenterol 1997; 112(Suppl.): A63(Abstract).
5. Prach AT, MacDonald TA, Hopwood DA, Johnston DA. Increasing incidence of Barrett's oesophagus: education, enthusiasm, or epidemiology. Lancet 1997; 350: 933.
6. Xia HH-X, Talley NJ. Helicobacter pylori infection, reflux esophagitis, and atrophic gastritis: an unexplored triangle. Am J Gastroenterol 1998; 93: 394-400.
7. Vicari J, Falk GW, Richter JE. Helicobacter pylori and acid peptic disorders of the esophagus: is it conceivable? Am J Gastroenterol 1997; 92: 1097-102.
8. O'Connor HJ, Cunnane K. Helicobacter pylori and gastrooesophageal reflux disease - a prospective study. Ir J Med Sci 1994; 163: 369-73.
9. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux oesophagitis. Gastroenterology 1997; 112: 1442-7.
10. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995; 90: 1401-6.
11. Verdu EF, Armstrong D, Fraser R, et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995; 36: 539-43.
12. Befrits R, Granstrom M, Rylander M, Rubio C. Helicobacter pylori in 205 consecutive endoscopy patients. Scand J Infect Dis 1993; 25: 185-91.
13. Boixeda D, Gisbert JP, Canton R, Alvarez Baleriola I, Gil Grande LA, Martinde Argila YC. Is there any association between Helicobacter pylori infection and gastroesophageal reflux disease? Med Clin (Barc) 1995; 105: 774-7.
14. Borkent MV, Beker JA. Treatment of ulcerative reflux oesophagitis with colloidal bismuth subcitrate in combination with cimetidine. Gut 1988; 29: 385-9.
15. Cheng EH, Bermanski P, Silversmith M, et al. Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal ulcer. Arch Intern Med 1989; 149: 1373-5.
16. Csendes A, Smok G, Cerda G, Burdiles P, Mazza D, Csendes P. Prevalence of Helicobacter pylori infection in 190 control subjects and in 236 patients with gastroesophageal reflux, erosive esophagitis or Barrett's esophagus. Dis Esophagus 1997; 10: 38-42.
17. De Koster E, Ferhat M, Deprez C, Deltenre SM, H. pylori, gastric histology and gastro-esophageal reflux disease. Gastroenterol 1995; 108(Suppl.): A81(Abstract).
18. Francoual S, Lamy P, Le Quintrec Y, et al. Helicobacter pylori: has it a part in the lesion of the gastroesophageal reflux? J Infect Dis 1990; 162: 1414-5.
19. Galimov O, Fyodorov S, Nurtdinov M, Scumkin A. Helicobacter infection in esophageal reflux (ER). Gut 1996; 39(Suppl. 3): A193(Abstract).
20. Goldblum JR, Vicari JJ, Falk GW, et al. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998; 114: 633-9.
21. Grebenev AL. Helicobacter pylori (Hp) and reflux esophagitis. Am J Gastroenterol 1994; 89: 1372.
22. Hackelsberger A, Schultze V, Gunther T, et al. H. pylori prevalence in reflux esophagitis - a case-control study. Gastroenterol 1997; 112(Suppl.): A137(Abstract).
23. Lee J, Breslin N, O'Morain C. Helicobacter pylori (HP) infection, cigarette smoking and alcohol consumption in reflux oesophagitis. Gut 1996; 39(Suppl. 2): A29(Abstract).
24. Liston R, Pitt MA, Banarjee AK. Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Postgrad Med J 1996; 72: 221-3.
25. Marshall BJ, McGechie DB, Rogers PA, Glancy RJ. Pyloric campylobacter infection and gastroduodenal disease. Med J Aust 1985; 142: 439-44.
26. McCallum RW, De Luca V, Marshall BJ, Prakash C. Prevalence of Campylobacter-like organisms in patients with gastro-esophageal reflux disease versus normals. Gastroenterology 1987; 92: 1524.
27. Mihara M, Haruma K, Kamada T, et al. Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis. Gut 1996; 39(Suppl. 2): A94(Abstract).
28. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997; 40: 9-13.
29. Ohara S, Koike T, Sekine H, et al. Prevalence of Helicobacter pylori infection and gastric mucosal atrophy in patients with reflux esophagitis in Japan. Gastroenterol 1997; 112 (Suppl.): A241 (Abstract).
30. Peitz U, Aygen S, Hennemann O, et al. Helicobacter pylori infection in young dyspeptic patients referred for upper gastrointestinal endoscopy. Gut 1995; 37(Suppl. 1): A25(Abstract).
31. Pieramico O, Zanetti MV. Role of H. plyori infection in gastrocsophageal reflux disease. Gut 1997; 41(Suppl. 1): A24(Abstract).
32. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Eskes SA, Meuwissen SGM. H. pylori. GERD and the efficacy of omeprazole therapy. Gastroenterol 1997; 112(Suppl.): A282(Abstract).
33. Sekiguchi T, Shirota T, Horikoshi T, et al. Helicobacter pylori infection and severity of reflux. Gastroenterol 1996; 110(Suppl.): A755(Abstract).
34. Vicari JJ, Falk GW, Goldblum JR, et al. H. pylori is not a pathogenic factor in GERD or its complications. Gastroenterol 1997; 112(Suppl.): A322(Abstract).
35. Walker SJ, Birch PJ, Stewart M, Stoddard CJ, Hart CA, Day DW. Patterns of colonisation of Campylobacter pylori in the oesophagus, stomach and duodenum. Gut 1989; 30: 1334-8.
36. Werdmuller BFM, Loffeld RJLF. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997; 42: 103-5.
37. - strains predominate in gastroesophageal reflux disease, Barrett's esophagus, and esophageal dysplasia/adenocarcinoma. Gastroenterol 1997; 112(Suppl.): A283(Abstract).
38. Awad R, Comacho S, Toriz A, Bernal F, Abdo M. Is there a role for Helicobacter pylori in gastroesophageal reflux disease? A 24 hour ambulatory combined pH and manometry study. Gastroenterol 1997; 112(Suppl.): A62(Abstract).
39. Stewart RJ, Boston VE, Dodge JA, et al. Campylobacter pylori and reflux oesophagitis. Acta Paediatr Scand 1990; 79: 107.
40. Rosioru C, Glassman MS, Halata MS, Schwarz SM. Esophagitis and Helicobacter pylori in children: incidence and therapeutic implications. Am J Gastroenterol 1993; 88: 510-13.
41. Cargill G, Atlan P, Tudor D, Regnault C. Association of Helicobacter pylori and reflux esophagitis in symptomatic children. Gastroenterol 1994; 106(Suppl.): A 59(Abstract).
42. Freston JW, Malagelada JR, Peterson H, McCloy RF. Critical issues in the management of gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 1995; 7: 577-86.
43. Schütze K, Hentschel E, Dragosics B, Hirschl AM. Helicobacter pylori reinfection with identical organisms: transmission by the patients' spouses. Gut 1995; 36: 831-3.
44. Sacca N, De Medici A, Rodino S, De Siena M. Giglio A. Reflux esophagitis: a complication of Helicobacter pylori (HP) eradication therapy? Gut 1996; 39(Suppl. 3): A35(Abstract).
45. Di Mario F. The appearance of esophagitis in duodenal ulcer patients after eradication of Helicobacter pylori (HP) infection. Gut 1997; 41(Suppl. 1): A98(Abstract).
46. Csendes A, Oster M, Moller JT, et al. Gastro-oesophageal reflux in duodenal ulcer patients before and after vagotomy. Ann Surg 1978; 188: 804-8.
47. Boyd EJS. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996; 91: 1539-43.
48. Flook D, Stoddard DJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. Br J Surg 1985; 72: 804-7.
49. Bateson MC, Bouchier IAD. The association of oesophagitis with disease of the stomach and duodenum. Postgrad Med J 1981; 57: 217-18.
50. O'Connor HJ, McGee C, Mehana N, Cunnane K. Prevalence of gastro-oesophageal reflux disease (GORD) in H. pyloripositive peptic ulcer disease and the impact of eradication therapy. Endoscopy 1997; 29: E15(Abstract).
51. Genta RM, Huberman RM, Graham DY. The gastric cardia in Helicobacter pylori infection. Hum Pathol 1994; 25: 915-19.
52. El-Omar EM, Penman ID, Ardill JES, et al. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease. Gastroenterology 1995; 109: 681-91.
53. Lundell L, Ruth M, Sandberg N, Bove-Nielsen M. Does massive obesity promote abnormal gastroesophageal reflux? Dig Dis Sci 1995; 40: 1632-5.
54. Allescher HD, Stoschus B, Wunsch E, Schusdziarri V, Classen M. Effect of human gastrin-17 with and without acid suppression on human esophageal motility. Z Gastroenterol 1995; 33: 385-91.
55. Correa P, Haenszel W, Cuello C, et al. Gastric precancerous process in a high risk population: cohort follow-up. Cancer Res 1990; 50: 4737-40.
56. Valle J, Kekki M, Sipponen P, Ihamäki T, Siurala M. Longterm course and consequences of Helicobacter pylori gastritis. Results of a 32-year follow-up study. Scand J Gastroenterol 1996; 31: 546-50.
57. Niemala S, Karttunen T, Kerola T. Helicobacter pylori-associated gastritis - evolution of histologic changes over 10 years. Scand J Gastroenterol 1995; 30: 542-9.
58. Villako K, Kekki M, Maaroos H-I, et al. A 12-year follow-up study of chronic gastritis and Helicobacter pylori in a population-based random sample. Scand J Gastroenterol 1995; 30: 964-7.
59. Kuipers EJ, Uyterlinde AM, Pena AS, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995; 345: 1525-8.
60. Maton PN. Omeprazole. N Engl J Med 1991; 324: 965-75.
61. Lamberts R, Creutzfeldt W, Struber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
62. Dent J, Yeomans ND, Mackinnon M, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis. A controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590-8.
63. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Longterm treatment with omeprazole for refractory reflux oesophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
64. Solcia E, Fiocca R, Havu N, Dalvag A, Carlsson R. Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. Digestion 1992; 51(Suppl. 1): 82-92.
65. Logan RPH, Walker MM, Misiewicz JJ, Gummett PA, Karim QN, Baron JH. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-16.
66. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996; 334: 1018-22.
67. Lundell L, Havu N, Andersson A, et al. Gastritis development and acid suppression therapy revisited. Results of a randomised clinical study with long-term follow-up. Gastroenterol 1997; 112(Suppl.): A28(Abstract).
68. Berstad AE, Hatlebakk JG, Maartmann-Moe H, et al. Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole. Gut 1997; 4: 740-7.
69. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997; 112: 707-17.
70. 2-receptor antagonists and antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729-34.
71. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120-4.
72. Tsujii M, Kawano S, Tsuji S, et al. Mechanism of gastric mucosal damage induced by ammonia. Gastroenterology 1992; 102: 1881-8.
73. Sachs G. Gastritis, Helicobacter pylori, and proton pump inhibitors. Gastroenterology 1997; 112: 1033-6.
74. Ishizuka J, Martinez J, Townsend CM, Thompson JC. The effect of gastrin on growth of human stomach cancer cells. Ann Surg 1992; 215: 528-35.
75. Tham TCK, Chen L, Dennison N, et al. Effect of Helicobacter pylori eradication on antral somatostatin cell density in humans. Eur J Gastroenterol Hepatol 1998; 10: 289-91.
76. El-Nujumi A, Williams C, Ardill JE, Oien K, McColl KEL. Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment. Gut 1998; 42: 159-65.
77. Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111: 655-65.
78. Azuma T, Konishi J, Tanaka Y. Contribution of HLA-DQA gene to host's response against Helicobacter pylori. Lancet 1994; 343: 542-3(Letter).
79. Cederberg C, Thomson AB, Mahachai V, et al. Effects of oral omeprazole on 24-hour intragastric acidity in duodenal ulcer patients. Gastroenterology 1992; 103: 913-18.
80. Cederberg C, Röhss K, Lundborg P, Olbe L. Effect of once daily intravenous and oral omeprazole on 24-hour intragastric acidity in healthy subjects. Scand J Gastroenterol 1993; 28: 179-84.
81. Labenz J, Tillenburg B, Peitz U, et al. Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer. Gastroenterology 1996; 110: 725-32.
82. Labenz J, Tillenburg B, Peitz U, et al. Efficacy of omeprazole one year after cure of Helicobacter pylori infection in duodenal ulcer patients. Am J Gastroenterol 1997; 92: 576-8.
83. Labenz J, Tillenburg B, Peitz U, et al. Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer. Gut 1997; 41: 33-6.
84. Carlsson R, Bate C, Dent J, et al. Does H. pylori infection influence the response to treatment with acid inhibition in patients with gastroesophageal reflux disease (GERD)? Scand J Gastroenterol 1997; 32(Suppl. 224): F70(Abstract).
85. Pfeiffer A, Kromer W, Friemann J, et al. Muscarinic receptors in gastric mucosa are increased in peptic ulcer disease. Gut 1995; 36: 813-18.
86. Ladas SD, Katsogridakis J, Malamou H, Gionnopoulou H, Kesse-Elia M, Raptis SA. Effect of Helicobacter pylori eradication on duodenogastric reflux. Gut 1994; 35(Suppl. 5): S3(Abstract).
87. Wilson KT, Ramanujam KS, Mobley HLT, Musselman RF, James SP, Meltzer SJ. Helicobacter pylori stimulates inducible nitric oxide synthase expression and activity in a murine macrophage cell line. Gastroenterology 1996; 111: 1524-33.
88. Cave DR, Vargas M. Effect of a Campylobacter pylori protein on acid secretion by parietal cells. Lancet 1989; ii: 187-9.
89. Moss SF, Legon S, Bishop AE, Polak JM, Calam J. Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancer 1992; 340: 930-2.
90. Lambert JR, Midolo P, Prichard PJ. Savage J, Bampton P. Helicobacter pylori infection causes hypergastrinaemia during omeprazole therapy. Gut 1995; 37(Suppl. 1): A59(Abstract).
91. Labenz J, Malfertheiner P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 1997; 41: 277-80.
92. de Cothi GGA, Newbold KM, O'Connor HJ. Campylobacterlike organisms and heterotopic gastric mucosa in Meckel's diverticula. J Clin Pathol 1989; 42: 132-4.
93. Winters C, Spurling TJ, Chobanian SJ, et al. Barrett's esophagus: a prevalent, occult complication of gastro-esophageal reflux disease. Gastroenterology 1987; 92: 118-24.
94. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997; 92: 212-15.
95. Abbas Z, Hussainy AS, Ibrahim F, Jafri SMW, Shaikh H, Khan AH. Barrett's oesophagus and Helicobacter pylori. J Gastroenterol Hepatol 1995; 10: 331-3.
96. Ferreres JC, Fernandez F, Rodriguez-Vives A, et al. Helicobacter pylori in Barrett's esophagus. Histol Histopathol 1991; 6: 403-8.
97. Gelrud D, Guelrud M, Mendoza S, Essenfeld E. Incidencia de Helicobacter pylori en esofago de Barrett. GEN 1991; 45: 111-13.
98. GOSPE. Precancerous Lesions of the Esophagus Task Force Italy. Helicobacter pylori in Barrett's eosophagus. Histopathology 1991; 18: 568-70.
99. Justin TA, Steele RJC. Helicobacter infection is associated with oesophagitis in patients with Barrett's oesophagus. Gut 1994; 15(Suppl. 1): AS(Abstract).
100. Kogan Z, Corti R, Cabane A, et al. Helicobacter pylori en esofago de Barrett. Acta Gastroent Latinoamer 1992; 22: 215-19.
101. Loffeld RJLF, Ten Tije BJ, Arends JW. Prevalence and significance of Helicobacter pylori in patients with Barrett's esophagus. Am J Gastroenterol 1992; 87: 1598-600.
102. Paull G, Yardley JH. Gastric and esophageal Campylobacter pylori in patients with Barrett's esophagus. Gastroenterology 1988; 95: 216-18.
103. Ricaurte O, Flejou JF, Vissuzaine C, et al. Helicobacter pylori infection in patients with Barrett's oesophagus: a prospective immunohistochemical study. J Clin Pathol 1996; 49: 176-7.
104. Talley NJ, Cameron AJ, Shorter RG, Zinsmeister AR, Phillips SF. Campylobacter pylori and Barrett's esophagus. Mayo Clin Proc 1988; 63: 1176-80.
105. Trakal E, Ortiz GA, Butti ALL, Armando RSR. Organismos tipo Campylobacter en el esofago de Barrett. Acta Gastroent Latinoamer 1987; 17: 85-96.
106. Wright TA, Kingsnorth AN. High incidence of Helicobacter pylori colonisation of Barrett's oesophagus. Gut 1995; 36(Suppl. 1): A38(Abstract).
107. Weston AP, Cherian R, Horvat RT, Lawrinenko V, Dixon A, McGregor D. Mucosa-associated lymphoid tissue (MALT) in Barrett's esophagus: prospective evaluation and association with gastric MALT, MALT lymphoma, and Helicobacter pylori. Am J Gastroenterol 1997; 92: 800-4.
108. Young MA, Kim R, Clark MR, et al. The incidence of premalignant markers of esophageal cancer is increased in Barrett's patients with Helicobacter pylori (lip). Gastroenterol 1996; 110(Suppl.): A618(Abstract).